Crescent Biopharma (CBIO) insider reports RSU and option awards

Rhea-AI Filing Summary

Crescent Biopharma’s Chief Scientific Officer reports new equity grants. On December 15, 2025, the officer acquired 17,507 and 5,000 Ordinary Shares, for a total of 22,507 Ordinary Shares beneficially owned directly after the transactions.

The filing also discloses a stock option grant for 70,025 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. These options vest in 1/48th monthly installments from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years, in each case contingent on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinkas Jan

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	12/15/2025		A		17,507	A	(1)	17,507	D
Ordinary Shares	12/15/2025		A		5,000	A	(1)	22,507	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.21	12/15/2025		A		70,025		(2)	12/15/2035	Ordinary Shares	70,025	$0	70,025	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

2. This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Jan Pinkas	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Crescent Biopharma (CBIO) report in this Form 4?

The Chief Scientific Officer of Crescent Biopharma, Inc. (CBIO) reported acquiring 17,507 and 5,000 Ordinary Shares on December 15, 2025, and a stock option grant for 70,025 Ordinary Shares.

How many Crescent Biopharma shares does the reporting person own after the transactions?

Following the reported transactions, the officer beneficially owns 22,507 Ordinary Shares directly, according to Table I of the filing.

What are the key terms of the Crescent Biopharma stock options granted on December 15, 2025?

The stock option gives the right to buy 70,025 Ordinary Shares at an exercise price of $13.21 per share and expires on December 15, 2035. It vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, subject to continued service.

How do the Crescent Biopharma RSUs for the Chief Scientific Officer vest?

The award of Restricted Stock Units (RSUs) vests in approximately equal three‑month installments through the four‑year anniversary of December 15, 2025, if the officer continues employment or service with Crescent Biopharma or its subsidiaries.

What role does the reporting person hold at Crescent Biopharma (CBIO)?

The reporting person is an officer of Crescent Biopharma, serving as the company’s Chief Scientific Officer.

Is the equity reported in this Crescent Biopharma Form 4 held directly or indirectly?

The 22,507 Ordinary Shares and the 70,025 stock options are reported as held with direct ownership.